Phase II Study of the Combination of Durvalumab (MEDI4736) (PDL1 Inhibitor) and Olaparib (PARP Inhibitor) in Advanced Cholangiocarcinoma After Initial Chemotherapy and Durvalumab (BIL-PPP)

• Status: RECRUITING
• Trial end date: 2028-08-01

Summary

The aim of this study is to investigate whether the combination of durvalumab and olaparib in the maintenance setting after initial chemotherapy and durvalumab will benefit patients with locally advanced or metastatic cholangiocarcinoma.

• Phase: PHASE2

Details

• Lead Sponsor: Australasian Gastro-Intestinal Trials Group
• Collaborators: AstraZeneca; Wayne Elphinstone Research Fund
• Treatments: durvalumab; olaparib